Skip to content

Study · Not a test of the peptide alone · 1995

1 result

Insulin-like growth factor-II as a paracrine growth factor in human neuroblastoma cells.

Leventhal PS, Randolph AE, Vesbit TE, Schenone A, Windebank A, Feldman EL

Experimental cell research1 Nov 1995Cited by 47 (Europe PMC)

PMID7589243 (opens in a new tab)DOI10.1006/excr.1995.1365 (opens in a new tab)PepBankPUB-07589243
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In SH-EP cells, des(1‑3)IGF-I stimulated growth with similar ligand specificity to IGF-II and IGF-I, and greater activity than insulin.

    In plain wordsIn cells, des(1‑3)IGF-I supported growth similarly to IGF-II and IGF-I, with greater activity than insulin.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseCell growth ligand specificity
    Study

    humann: not reported in source

    SH-EP neuroblastoma cells
    Comparator
    IGF-II, IGF-I and insulin
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Stimulation of cell growth via this receptor was also indicated by the ligand specificity for IGF analogs and insulin (IGF-II approximately IGF-I approximately des(1-3)IGF-I >> insulin).

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.